The aim of this study was to assess the suitability of Tc-99(m)-tetrof
osmin (tetrofosmin) scintigraphy as a diagnostic modality in patients
with Hodgkin's disease. Fourteen untreated patients with biopsy proven
Hodgkin's disease (clinical stage Ia-IVb) were investigated. Post-tre
atment investigations were also done in 7 of the 14 patients. Focal pa
thological tetrofosmin uptake was seen in 42 sites in the pre-treatmen
t studies. Computed tomography identified 36 pathological regions. The
tumour-to-background ratio ranged from 7.44 to 2.17 (mean 1.63). Foll
ow-up studies demonstrated a response to treatment, in that there was
a reduction in, or complete disappearance of, localized tetrofosmin up
take in regions previously pathological, and a decrease in tumour-to-b
ackground ratios. Tetrofosmin appears suitable for the localization of
lymphomatous lesions, especially supradiaphragmatic ones, and for the
follow-up of therapeutic response.